A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

NCT05861947 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Patient recruitment problems

Conditions

Relapse
Advanced Malignant Neoplasm
Non Small Cell Lung Cancer
Gastric Cancer
Urothelial Carcinoma
Kidney Cancer
Colon Cancer
Esophagus Cancer

Interventions

DRUG: AUR106

Sponsor

Aurigene Discovery Technologies Limited